DHT is a potent agonist of the AR, and is in fact the most potent known endogenous ligand of the receptor. It has an affinity (K d ) of to nM for the human AR, which is about 2- to 3-fold higher than that of testosterone (K d = to nM)  and 15–30 times higher than that of adrenal androgens .  In addition, the dissociation rate of DHT from the AR is 5-fold slower than that of testosterone.  The EC 50 of DHT for activation of the AR is nM, which is about 5-fold stronger than that of testosterone (EC 50 = nM).  In bioassays , DHT has been found to be - to 10-fold more potent than testosterone. 
Transdermal patches (adhesive patches placed on the skin) may also be used to deliver a steady dose through the skin and into the bloodstream. Testosterone-containing creams and gels that are applied daily to the skin are also available, but absorption is inefficient (roughly 10%, varying between individuals) and these treatments tend to be more expensive. Individuals who are especially physically active and/or bathe often may not be good candidates, since the medication can be washed off and may take up to six hours to be fully absorbed. There is also the risk that an intimate partner or child may come in contact with the application site and inadvertently dose himself or herself; children and women are highly sensitive to testosterone and can suffer unintended masculinization and health effects, even from small doses. Injection is the most common method used by individuals administering AAS for non-medical purposes.